open access

Vol 16, No 1 (2014)
Review articles
Published online: 2014-11-13
Get Citation

Cilostazol in the therapy of lower limb ischemia

Jerzy Chudek, Damian Ziaja
Chirurgia Polska 2014;16(1):6-11.

open access

Vol 16, No 1 (2014)
Review articles
Published online: 2014-11-13

Abstract

Cilostazol is a selective, reversible inhibitor of phosphodiesterase type 3, which inhibits platelet aggregation and exerts a vasodilation effect. These therapeutic properties justified its use in the conservative treatment of chronic lower limb ischemia. Cilostazol is used worldwide for over 15 years, but has not been widely available in Poland.

Randomized clinical trials with placebo showed that the drug used at a dose of 100 mg twice daily increases the claudication distance of by an average of 30–40 meters. In addition, clinical observations indicate its potential benefits in patients with critical ischemia of the lower limbs, pointing out lower incidence of amputation and acceleration of ulcers healing.

The use of cilostazol, like aspirin, reduces the risk of stroke, and in patients after endovascular treatment (the femoro-popliteal stenting) reduces the risk of stent thrombosis and restenosis. The potential benefits of cilostazol in the combination with other antiplatelet agents are being questioned and remain subject to scientific debates.

Recently published studies indicate the potential benefits related to slowing progression of Alzheimer’s disease and reduced pulmonary artery pressure in patients treated with cilostazol.

This article summarizes current knowledge on the use of cilostazol and its limitations in the treatment of chronic ischemia of the lower limbs, and presenting the recommendations of the European Medicines Agency issued in 2013.

Abstract

Cilostazol is a selective, reversible inhibitor of phosphodiesterase type 3, which inhibits platelet aggregation and exerts a vasodilation effect. These therapeutic properties justified its use in the conservative treatment of chronic lower limb ischemia. Cilostazol is used worldwide for over 15 years, but has not been widely available in Poland.

Randomized clinical trials with placebo showed that the drug used at a dose of 100 mg twice daily increases the claudication distance of by an average of 30–40 meters. In addition, clinical observations indicate its potential benefits in patients with critical ischemia of the lower limbs, pointing out lower incidence of amputation and acceleration of ulcers healing.

The use of cilostazol, like aspirin, reduces the risk of stroke, and in patients after endovascular treatment (the femoro-popliteal stenting) reduces the risk of stent thrombosis and restenosis. The potential benefits of cilostazol in the combination with other antiplatelet agents are being questioned and remain subject to scientific debates.

Recently published studies indicate the potential benefits related to slowing progression of Alzheimer’s disease and reduced pulmonary artery pressure in patients treated with cilostazol.

This article summarizes current knowledge on the use of cilostazol and its limitations in the treatment of chronic ischemia of the lower limbs, and presenting the recommendations of the European Medicines Agency issued in 2013.

Get Citation

Keywords

cilostazol, chronic lower limb ischemia, atherosclerosis of the lower extremities, intermittent claudication

About this article
Title

Cilostazol in the therapy of lower limb ischemia

Journal

Chirurgia Polska (Polish Surgery)

Issue

Vol 16, No 1 (2014)

Pages

6-11

Published online

2014-11-13

Bibliographic record

Chirurgia Polska 2014;16(1):6-11.

Keywords

cilostazol
chronic lower limb ischemia
atherosclerosis of the lower extremities
intermittent claudication

Authors

Jerzy Chudek
Damian Ziaja

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaBy "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl